High levels of PROM1 (CD133) transcript are a potential predictor of poor prognosis in medulloblastoma

Neuro-Oncology

Volumn 13, Issue 5, 2011, Pages 500-508

  Raso, Alessandro ^a   Mascelli, Samantha ^a   Biassoni, Roberto ^a   Nozza, Paolo ^a   Kool, Marcel ^b   Pistorio, Angela ^a   Ugolotti, Elisabetta ^a   Milanaccio, Claudia ^a   Pignatelli, Sara ^a   Ferraro, Manuela ^a   Pavanello, Marco ^a   Ravegnani, Marcello ^a   Cama, Armando ^a   Garré, Maria Luisa ^a   Capra, Valeria ^a  

^a G GASLINI INSTITUTE   (Italy)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Cancer stem cells; Medulloblastoma; PROM1; q PCR

Indexed keywords

CD133 ANTIGEN;

ARTICLE; CANCER SURVIVAL; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMAN; HUMAN TISSUE; MALE; MEDULLOBLASTOMA; METASTASIS; MICROARRAY ANALYSIS; NUCLEOTIDE SEQUENCE; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE; PRESCHOOL CHILD; PROGNOSIS; PROGRESSION FREE SURVIVAL;

ANTIGENS, CD; CEREBELLAR NEOPLASMS; CHILD, PRESCHOOL; FEMALE; GENE EXPRESSION PROFILING; GLYCOPROTEINS; HUMANS; MALE; MEDULLOBLASTOMA; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PEPTIDES; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 79959925147     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nor022     Document Type: Article

References (47)

1. Kuhl J, Doz F, Taylor RE. Embryonic tumors. In: Walker, DA, Perilongo, G, Punt, JAG, Taylor, RE, eds. Brain, and Spinal Tumors of Childhood. London: Arnold; 2004:314-330.
2. Giangaspero F, Eberhart CG, Haapasalo H, Pietsch T, Wiestler OD, Ellison DW. Medulloblastoma. In: Louis, DN, Ohgaki, H, Wiestler, D, Cavenee, WK, eds. WHO Classification of Tumours of the Central Nervous System. Lyon: IARC; 2007:132-140.
3. Eberhart CG. In search of the medulloblast: neural stem cells and embryonal brain tumors. Neurosurg Clin N Am 2007;18:59-69. (Pubitemid 46161192)
4. Bailey P, Cushing H. Medulloblastoma cerebelli: a common type of midcerebellar glioma of chidhood. Arch Neurol Psychiatry 1925;14:192-224.
5. Singh SK, Hawkins C, Clarke ID, et al. Identification of human brain tumour initiating cells. Nature 2004;432:396-401. (Pubitemid 39551674)
6. Hemmati HD, Nakano I, Lazareff JA, et al. Cancerous stem cells can arise from pediatric brain tumors. Proc Natl Acad Sci USA 2003;100:15178-15183. (Pubitemid 37518036)
7. Galli R, Binda E, Orfanelli U, et al. Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Research 2004;64:7011-7021. (Pubitemid 39331011)
8. Raso A, Negri F, Gregorio A, et al. Successful isolation and long-term establishment of a cell line with stem cell-like features from an anaplastic medulloblastoma. Neuropathol Appl Neurobiol 2008;34:306-315. (Pubitemid 351590865)
9. Jordan CT, Guzman ML, Noble M. Cancer stem cells. N Engl J Med 2006;355:1253-1261. (Pubitemid 44427449)
10. Neuzil J, Stantic M, Zobalova R, et al. Tumour-initiating cells vs. cancer 'stem' cells and CD133: what's in the name? Biochem Biophys Res Commun 2007;355:855-859. (Pubitemid 46366906)
11. Miraglia S, Godfrey W, Yin AH, et al. A novel five-transmembrane hematopoietic stem cell antigen: isolation, characterization, and molecular cloning. Blood 1997;90:5013-5021. (Pubitemid 28007218)
12. Corbeil D, Röper K, Hellwig A, et al. The human AC133 hematopoietic stem cell antigen is also expressed in epithelial cells and targeted to plasma membrane protrusions. J Biol Chem 2000;275:5512-5520. (Pubitemid 30115186)
13. Zhang QB, Ji XY, Huang Q, et al. Differentiation profile of brain tumor stem cells: a comparative study with neural stem cells. Cell Res 2006;16:909-915. (Pubitemid 44973578)
14. Liu G, Yuan X, Zeng Z, et al. Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol Cancer 2006;5:67.
15. Hambardzumyan D, Squarto M, Holland EC. Radiation resistance and stem-like cells in brain tumors. Cancer Cell 2006;10:454-456. (Pubitemid 44854752)
16. Bao S, Wu Q, McLendon RE, et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006;444:756-760. (Pubitemid 44949604)
17. Zeppernick F, Ahmadi R, Campos B, et al. Stem cell marker CD133 affects clinical outcome in glioma patients. Clin Cancer Res 2008;14:123-129. (Pubitemid 351377986)
18. Garrè ML, Cama A, Bagnasco F, et al. Medulloblastoma variants: agedependent occurrence and relation to Gorlin syndrome-a new clinical perspective. Clin Cancer Res 2009;15:2463-2471.
19. Grundy RG, Wilne SA, Weston CL, et al. Primary postoperative chemotherapy without radiotherapy for intracranial ependymoma in children: the UKCCSG/SIOP prospective study. Lancet Oncol 2007;8:696-705. (Pubitemid 47189085)
20. Garre' ML, Massimino M, Cefalo G, et al. High-risk malignant CNS tumours in infants: standard vs myeloablative chemotherapy: the experience of the Italian cooperative study for children >3 years of age. Neurooncol 2003;1:40.
21. Packer RJ, Gajjar A, Vezina G, et al. Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma. J Clin Oncol 2006;24:4202-4208. (Pubitemid 46622300)
22. Dallorso S, Dini G, Ladenstein R, et al. Evolving role of myeloablative chemotherapy in the treatment of childhood brain tumours. Bone Marrow Transplant 2005;35:S3131-S34.
23. Chang CH, Housepian EM, Herbert C. An operative staging system and a megavoltage radiotherapeutic technic for cerebellar medulloblastomas. Radiology 1969;93:1351-1359.
24. Zuker M. Mfold web server for nucleic acid folding and hybridization prediction. Nucleic Acids Res 2003;31:3406-3415. (Pubitemid 37442169)
25. Santa Lucia J. A unified view of polymer, dumbbell, and oligonucleotide DNA nearest-neighbor thermodynamics. Proc Natl Acad Sci USA 1998;95:1460-1465.
26. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001;29:45.
27. Bustin SA. Absolute quantification of mRNA using real-time reverse transcription polymerase chain reaction assays. J Mol Endocrinol 2000;25:169-193.
28. Fiermonte G, Palmieri L, Todisco S, et al. Identification of the mitochondrial glutamate transporter: bacterial expression, reconstitution, functional characterization and tissue distribution of two human isoforms. J Biol Chem 2002;277:19289-19294. (Pubitemid 34967433)
29. Vandesompele J, De Preter K, Pattyn F, et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 2002;8:3.
30. Bustin SA, Benes V, Garson JA, et al. The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin Chem 2009;55:611-622.
31. Kool M, Koster J, Bunt J, et al. Integrated genomics identifies five medulloblastoma subtypes with distinct genetic profiles, pathway signatures and clinicopathological features. PLoS One 2008;3(8):e3088.
32. Baker SG. The central role of receiver operating characteristic (ROC) curves in evaluating tests for the early detection of cancer. J Natl Cancer Inst 2003;95:511-515. (Pubitemid 36511621)
33. Gajjar A, Hernan R, Kocak M, et al. Clinical, histopathologic, and molecular markers of prognosis: toward a new disease risk stratification system for medulloblastoma. J Clin Oncol 2004;22:984-993. (Pubitemid 41095029)
34. Jozwiak J, Grajkowska W, Wlodarski P. Pathogenesis of medulloblastoma and current treatment outlook. Med Res Rev 2007;27:869-890. (Pubitemid 350035122)
35. Rossi A, Caracciolo V, Russo G, et al. Medulloblastoma: from molecular pathology to therapy. Clin Cancer Res 2008;14:971-976. (Pubitemid 351302541)
36. Packer RJ, MacDonald T, Vezina G. Central nervous system tumors. Pediatr Clin North Am 2008;55:121-145. (Pubitemid 351173185)
37. Gandola L, Massimino M, Cefalo G, et al. Hyperfractionated accelerated radiotherapy in the Milan strategy for metastatic medulloblastoma. J Clin Oncol 2009;27:566-571.
38. Packer RJ, Rood BR, Macdonald TJ. Medulloblastoma: present concepts of stratification into risk groups. Pediatr Neurosurg 2003;39:60-67. (Pubitemid 36829097)
39. Gilbertson RJ. Medulloblastoma: signaling a change in treatment. Lancet Oncol 2004;5:209-218.
40. Mulhern RK, Palmer SL, Merchant TE, et al. Neurocognitive consequences of risk-adapted therapy for childhood medulloblastoma. Clin Oncol 2005;23:5511-5519.
41. Gottardo NG, Gajjar A. Current therapy for medulloblastoma. Curr Treat Options Neurol 2006;8:319-334. (Pubitemid 43942066)
42. Rutkowski S, von Bueren A, von Hoff K, et al. Prognostic relevance of clinical and biological risk factors in childhood medulloblastoma: results of patients treated in the prospective multicenter trial HIT'91. Clin Cancer Res 2007;13:2651-2657. (Pubitemid 46788032)
43. Lamont JM, McManamy CS, Pearson AD, et al. Combined histopathological and molecular cytogenetic stratification of medulloblastoma patients. Clin Cancer Res 2004;10:5482-5493. (Pubitemid 39100486)
44. Fan X, Eberhart CG. Medulloblastoma stem cells. J Clin Oncol 2008;26:2821-2827.
45. Mizrak D, Brittan M, Alison MR. CD133: molecule of the moment. J Pathol 2008;214:3-9.
46. Albright AL, Wisoff JH, Zeltzer PM, et al. Effects of medulloblastoma resections on outcome in children: a report from the Children's Cancer Group. Neurosurgery 1996;38:265-271. (Pubitemid 26030705)
47. Croker AK, Allan AL. Cancer stem cells: implications for the progression and treatment of metastatic disease. J Cell Mol Med 2008;12:374-390. (Pubitemid 351555122)